查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1549436

學名藥的日本市場評估:各用途，各類型，不同品牌，各給藥途徑，各流通管道，各地區，機會，預測(2018年度～2032年度)

Japan Generic Drugs Market Assessment, By Application, By Type, By Brand, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, FY2018-FY2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 125 Pages | 商品交期: 3-5個工作天內

價格

日本仿製藥市場規模預計將從 2024 財年的 127.2 億美元增至 2032 財年的 232.3 億美元，在預測期內（2024 財年至 2032 財年）複合年增長率為 7.81%。市場成長受到以下因素的支持：政府減少醫療保健支出的政策、出生率下降導致的人口老化以及製藥公司增加聯盟和夥伴關係以增加該國仿製藥的供應。

包括呼吸系統疾病和紊亂在內的慢性病的盛行率不斷上升，也推動了對日本仿製藥市場的需求。根據多芬醫學出版社2024年5月發表的文章，日本氣流阻塞的盛行率為3.8%至16.9%。這增加了對仿製藥的需求，因為它們在給藥途徑、強度、品質和給藥方面與品牌藥相當，同時為患者提供了經濟的替代方案。為了減少國民醫療保健支出，日本政府也實施了各種鼓勵仿製藥採用的政策。

此外，醫療保健專業人員和患者越來越多地使用產品也可能是由於人們對仿製藥帶來的好處的認識不斷提高，這推動了日本仿製藥市場的規模。此外，厚生勞動省也推出了仿製藥推廣措施，為2022年醫療費用調整做準備。

此外，2023 年 2 月發表在 Biomed Central 上的一項研究認為，隨著患者月收入的減少，門診醫院和門診處方中仿製藥的使用量會增加。

癌症、糖尿病和心血管疾病等疾病的盛行率不斷上升，推動了對仿製藥的需求。這些慢性病往往需要長期用藥，而仿製藥的使用可以讓患者以經濟有效的方式管理自己的病情，凸顯了仿製藥在慢性病管理中的重要角色。

政府支持的成長機會

日本政府正在增加對教育活動的投資，以提高公眾意識並促進仿製藥的使用。厚生勞動省也鼓勵大型藥品生產公司與中小型藥品生產商合併，促進仿製藥生產，確保穩定供應。該部也旨在振興製藥業，加速國內藥物開發。藥品是衛生系統的主要支出之一，降低藥品成本是政府和政策制定者減少開支、擴大醫療覆蓋範圍、改善藥品取得的當務之急，這是一項永恆的挑戰。因此，仿製藥的採用正在增加，對市場成長產生正面影響。

老年人口擴大帶動市場需求

過去幾十年來，人口老化增加了對仿製藥的關注，以降低醫療保健行業的成本。根據世界經濟論壇估計，日本近三分之一的人口年齡在65歲以上，超過十分之一的人口年齡在80歲以上。這種增長增加了該國對仿製藥的需求，因為老年人更容易患各種疾病和病症，需要定期用藥。仿製藥與原廠藥含有相同的活性成分，因此在具有與專利藥相同的給藥方法、功效、劑量和效果的同時，具有經濟高效性。因此，日本對仿製藥的偏好正在增加。

品牌仿製藥佔較大市佔率

各種慢性病盛行率的增加以及市場進入者推出的產品數量的增加正在支持日本仿製藥市場的成長。 2023年4月，持田製藥股份有限公司宣布推出曲普羅吸入溶液，用於治療肺動脈高壓。

本報告對日本仿製藥市場進行研究和分析，提供市場規模和預測、市場動態以及主要公司的現狀和前景。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 日本的學名藥市場預測(2018年度～2032年度)

  • 市場規模的分析與預測
    • 金額
    • 數量
  • 市場佔有率分析與預測
    • 各用途
    • 各類型
    • 不同品牌
    • 各給藥途徑
    • 各流通管道
    • 各地區
    • 市場佔有率分析:各企業(金額)(前五名公司和其他 - 2024年度)
  • 市場地圖分析(2024年度)
    • 各用途
    • 各類型
    • 不同品牌
    • 各給藥途徑
    • 各流通管道
    • 各地區

第5章 供需分析

第6章 進口和出口的分析

第7章 價值鏈分析

第8章 波特的五力分析

第9章 大環境分析

第10章 價格分析

第11章 市場動態

  • 推動市場要素
  • 市場課題

第12章 市場趨勢與發展

第13章 法規結構和革新

  • 生物有效性/生物學的同等性實驗
  • 法規當局的認證

第14章 專利的有效期限

第15章 案例研究

第16章 競爭情形

  • 市場領導者前五名公司的競爭矩陣
  • 前五名公司的SWOT分析
  • 主要企業前十大企業的形勢
    • Takeda Pharmaceutical Co., Ltd.
    • Teva Pharmaceuticals Industries Ltd.
    • Sun Pharma Japan Limited
    • Nichi-Iko Pharmaceutical Co., Ltd.
    • OHARA Pharmaceutical Co., Ltd.
    • DAIICHI SANKYO COMPANY, LIMITED
    • Meiji Seika Pharma
    • Biocon Biologics Limited
    • Mochida Pharmaceutical Co., Ltd.
    • NIHON GENERIC Co., Ltd.

第17章 策略性推薦

第18章 本公司相關資料，免責聲明

Product Code: MX11867

Japan generic drugs market is projected to witness a CAGR of 7.81% during the forecast period FY2024-FY2032, growing from USD 12.72 billion in FY2024 to USD 23.23 billion in FY2032. The market's growth is supported by government policies to reduce healthcare expenditure, expanding aging population due to low birth rates, and rising collaborations and partnerships by pharmaceutical companies to boost the availability of generic drugs in the country.

The growing prevalence of chronic diseases, including respiratory diseases and disorders, is also boosting the Japan generic drugs market demand. According to an article published in Dove Medical Press in May 2024, the prevalence of airflow obstruction in Japan is 3.8%-16.9%. This bolsters the requirement for generics as they are equivalent to their brand-name counterparts in route of administration, strength, quality, and dosage while providing patients with an economical alternative. To reduce the national healthcare expenditure, the Japanese government has also implemented various policies to encourage the adoption of generics.

Additionally, the growing utilization of products by both healthcare professionals and patients can also be attributed to the increasing awareness about the benefits offered by them, which, in turn, is boosting the Japan generic drugs market size. Additionally, the Ministry of Health, Labor and Welfare (MHLW) proposed measures to promote generics for FY2022 reimbursement reform.

Furthermore, a study published in Biomed Central in February 2023 observed that the rate of generic prescription utilization for outpatient in-hospital prescriptions and out-of-hospital prescriptions increased as the monthly personal incomes of patients decreased.

The increasing prevalence of diseases such as cancer, diabetes, and cardiovascular diseases is driving the demand for generic drugs. These chronic conditions often require long-term medication, and the use of generic drugs enables patients to manage their conditions in a cost-effective manner, thereby highlighting the vital role of generic drugs in managing chronic diseases.

Government Encouragement Provides Growth Opportunities

The Japanese government is increasingly investing in educational campaigns to bolster public awareness and boost the utilization of generic drugs. The country's health ministry is also encouraging bigger drug manufacturers to merge with the small ones to propel the production of generics and ensure a stable supply. The ministry also aims to revitalize the pharmaceutical industry to accelerate domestic drug development. Medications are one of the main expenses of the healthcare system; possible reduction in drug costs is an everlasting concern for the government and policymakers to reduce expenditures, extend medical coverage, and improve access to medications. Thus, augmenting the adoption of generic drugs and positively influencing the market's growth.

Expansion of the Aging Population Boosts Market Demand

Over the past few decades, a push toward generic drugs have been witnessed to reduce costs in the healthcare sector due to the growth of the aging population. As per the estimates of the World Economic Forum, almost a third of the Japanese population is older than 65, and more than 1 in 10 individuals in the country are 80 or older. This growth is augmenting the requirement for generic drugs in the country as the older population is more susceptible to various diseases and disorders and regularly needs medications. As the generic drugs carry the same active ingredient as their brand name counterparts, they have the same administration, efficacy, dosage, and effect as the patented drug while being economically efficient. Thus, the preference for generics is increasing in the country.

Branded Generics Account for Major Market Share

The rising prevalence of various chronic diseases and increasing product launches by market players are supporting the growth of the Japan generic drugs market. In April 2023, Mochida Pharmaceutical Co., Ltd. announced the launch of Treprost Inhalation Solution, indicated for pulmonary arterial hypertension. The product contains Treprostinil as the active ingredient. Pulmonary arterial hypertension is characterized by elevated pulmonary artery pressure caused by the hardening and narrowing of pulmonary arteries responsible for carrying blood from the heart to the lungs. Symptoms including dizziness, fatiguability, and palpations accompany the orphan refractory disease. The market players are actively investing in the launch of branded generics to manage and treat such chronic conditions in Japan.

Biosimilars Hold Significant Market Share

Various biosimilars are being launched in Japan to ensure the availability of economically efficient treatment options for patients combatting chronic diseases. In December 2023, Sandoz Group AG and Biocon Biologics Limited announced a partnership for promoting, distributing, and selling Adalimumab in Japan. Under the agreement, Sandoz holds exclusive rights for the distribution and sale of the subcutaneous injection of Adalimumab BS in Japan. Adalimumab, the biosimilar version of Humira, is indicated for rheumatoid arthritis. Such collaborations and partnerships are expected to support the segment's expansion and boost the Japan generic drugs market's growth. The adoption of biosimilars is rapidly increasing in the country due to the growing awareness about their efficacy and safety among the general population.

Future Market Scenario (FY2025-FY2032F)

As per the Japan generic drugs market analysis, the growth of the market is boosted by the ongoing efforts of the Japanese government to propel awareness about generics, the increasing prevalence of chronic diseases, and the rapid aging of the country's population. According to the Population Projections for Japan (2023) in the National Institute of Population and Social Security Research, the number of people of ages 75 and above will increase to 22.58 million in 2030. The increasing investments by pharma companies towards the expansion of their generic portfolios and the launch of new biosimilars in the country are further expected to provide lucrative growth opportunities to the market.

Key Players Landscape and Outlook

Increasing collaborations to ensure a consistent supply of generics in Japan is supporting the market's expansion. Due to the efficacy offered by generic drugs and the assurance of cost efficiency, they are becoming increasingly popular in Japan. In order to ensure their availability, Meiji Seika Pharma, Me Pharma Co., Ltd., and Medreich Limited announced collaboration in July 2023 to establish a sustainable business model for generics. Through this collaboration, the companies are determined to create a unique business model to ensure a steady supply of generic drugs at nominal prices while generating profits for their sustainability. The companies are dedicated towards refining their processes and building rigorous quality control systems to meet all the requirements of Japan.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Generic Drugs Market Outlook, FY2018-FY2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Application
      • 4.2.1.1. Neurovascular
      • 4.2.1.2. Cardiovascular
      • 4.2.1.3. Dermatology
      • 4.2.1.4. Oncology
      • 4.2.1.5. Diabetology
      • 4.2.1.6. Respiratory
      • 4.2.1.7. Others
    • 4.2.2. By Type
      • 4.2.2.1. Biosimilar Generics
      • 4.2.2.2. Small Molecule Generics
    • 4.2.3. By Brand
      • 4.2.3.1. Branded Generic
      • 4.2.3.2. Pure Generic
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
      • 4.2.4.3. Topical
      • 4.2.4.4. Others
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacy
      • 4.2.5.2. Retail Pharmacy
      • 4.2.5.3. Online Pharmacy
    • 4.2.6. By Region
      • 4.2.6.1. North [Hokkaido and Tohoku]
      • 4.2.6.2. Central [Kanto and Chubu]
      • 4.2.6.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
  • 4.3. Market Map Analysis, FY2024
    • 4.3.1. By Application
    • 4.3.2. By Type
    • 4.3.3. By Brand
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

  • 11.1. Market Drivers
  • 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

  • 13.1. Bioavailability/ Bioequivalence Studies
  • 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

  • 16.1. Competition Matrix of Top 5 Market Leaders
  • 16.2. SWOT Analysis for Top 5 Players
  • 16.3. Key Players Landscape for Top 10 Market Players
    • 16.3.1. Takeda Pharmaceutical Co., Ltd.
      • 16.3.1.1. Company Details
      • 16.3.1.2. Key Management Personnel
      • 16.3.1.3. Products and Services
      • 16.3.1.4. Financials (As Reported)
      • 16.3.1.5. Key Market Focus and Geographical Presence
      • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 16.3.2. Teva Pharmaceuticals Industries Ltd.
    • 16.3.3. Sun Pharma Japan Limited
    • 16.3.4. Nichi-Iko Pharmaceutical Co., Ltd.
    • 16.3.5. OHARA Pharmaceutical Co., Ltd.
    • 16.3.6. DAIICHI SANKYO COMPANY, LIMITED
    • 16.3.7. Meiji Seika Pharma
    • 16.3.8. Biocon Biologics Limited
    • 16.3.9. Mochida Pharmaceutical Co., Ltd.
    • 16.3.10. NIHON GENERIC Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Japan Generic Drugs Market, By Value, In USD Billion, FY2018-FY2032F
  • Figure 2. Japan Generic Drugs Market, By Volume, In Number of Prescriptions, FY2018-FY2032F
  • Figure 3. Japan Generic Drugs Market Share (%), By Application, FY2018-FY2032F
  • Figure 4. Japan Generic Drugs Market Share (%), By Type, FY2018-FY2032F
  • Figure 5. Japan Generic Drugs Market Share (%), By Brand, FY2018-FY2032F
  • Figure 6. Japan Generic Drugs Market Share (%), By Route of Administration, FY2018-FY2032F
  • Figure 7. Japan Generic Drugs Market Share (%), By Distribution Channel, FY2018-FY2032F
  • Figure 8. Japan Generic Drugs Market Share (%), By Region, FY2018-FY2032F
  • Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 11. By Brand Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024